Teva and Allergan Documents

 
Dates 2003-2022; bulk 2008-2018

Overview and Background

Teva Pharmaceuticals, an Israeli company, is one of the United States’ biggest manufacturers of generic opioids, including oxycodone. Teva also manufactures the branded fentanyl products Actiq and Fentora. Ireland-based Allergan formerly made Norco- and Kadian-branded and generic opioids. Teva acquired Cephalon in 2011 as a wholly-owned subsidiary of Teva Ltd., which added Actiq and Fentora to Teva’s portfolio. In 2016, Teva acquired Allergan’s generics business, Actavis. Allergan/Actavis was the second largest manufacturer to supply generic opioids to the United States, following Mallinckrodt. Allergan was acquired by AbbVie in 2019. On November 23, 2022, attorneys general in eight states announced that proposed nationwide settlements totaling $6.6 billion had been reached with Teva and Allergan, resolving allegations that they contributed to the opioid crisis by illegally marketing their opioids and failing to maintain effective diversion controls. The nationwide settlements, which became effective in August 2023, call for Teva to pay a total of $4.24 billion over 13 years and Allergan to pay $2.37 billion over seven years. The settlements prohibit Teva and Allergan from promoting opioids, directly and through front groups, and from engaging in opioid-related lobbying activities. The settlements also require the companies to turn over for public disclosure millions of internal documents they produced in the litigation.

Documents

The records in this collection are subject to public disclosure under the terms of the Teva and Allergan Global Settlement Agreements. UCSF and JHU have been appointed to serve as the public repository for these documents. Documents in the collection include emails, spreadsheets, presentations, reports, sales training materials, speaker program records, clinical study documentation, research articles, grant documentation, depositions and exhibits, trial exhibits, trial transcripts, privilege logs, and other court documents. The collection ultimately will contain more than one million documents. Processed documents are being made public on a rolling basis with monthly releases expected from 2024-2026. Names frequently appearing in the documents include Matthew Day, Susan Larijani, Arvind Narayana, Terrence Terifay, Paula Castagno Williams, Jamie Warner, Deborah Bearer, and Cynthia Condodina. Protected information in the documents (including PII and PHI) was redacted by Teva and Allergan according to the disclosure terms of the settlement agreements. OIDA team members reviewed a sample of the documents to verify appropriate redaction of PII and PHI, adding additional redactions when warranted.  

Where to Start...

Teva Depositions

Key Legal Documents

Teva and Allergan settlement documents
Teva document disclosure terms in Exhibit P of the Teva Global Opioid Settlement Agreement
Allergan document disclosure terms in Exhibit P of the Allergan Global Settlement Agreement

Notable Teva and Allergan Documents and Related Topics

Fentanyl Forerunner
Pseudoaddiction
Risk Mitigation

Related Resources

• Massachusetts Office of the Attorney General. (2022, Nov. 23). “AG Healey Announces $6.6 Billion Nationwide Settlement with Teva and Allergan over Claims of Illegally Marketing Opioids.”
• Hoffman, Jan. (2022, July 29). “Allergan Reaches Tentative $2.37 Billion Deal to Settle Opioid Suits.” The New York Times. (registration may be required)
• Hoffman, Jan. (2022, July 26). “Teva Reaches Tentative $4.25 Billion Settlement Over Opioids.” The New York Times. (registration may be required)

See our annotated bibliography for more resources providing context on Teva and Allergan litigation.